K. Ranga Rama Krishnan

"This is an exciting time for medicine in general and mental health in particular. There is a remarkable explosion in knowledge about the brain, our genes, and treatment (both psychosocial and biological) of mental disorders. There is also a rapid change in how we communicate with each other. The advent of the Internet has greatly changed how we live and interact with each other. At the same time there is increasing difficulty in being able to provide state-of-the-art services to patients and therefore the need for developing better and more efficient care delivery systems.

"Our primary missions include clinical care, teaching and research. We plan to play a major role in shaping the developments in our field, keeping in mind that the sole and ultimate mission is improving our understanding and treatment of patients with illness. Our department is fortunate in being able to play a major role in these developments. We are a broad, diverse and deep department. Our members come from a variety of disciplines besides psychiatry, including medical psychology, social work, nursing, toxicology, epidemiology, molecular biology and neuroscience.

"For residents this presents a wealth of opportunities, a diverse and eclectic perspective with the ability to pursue a focused line of training in almost any arena in psychiatry. I have a personal commitment to training residents and--with that in mind--meet with the residents regularly to help them develop the ability to meet the challenges and opportunities of the emerging changes in our field while at the same time retain their core humanistic values."

Adrian C. Angold (Child & Adolescent Psych)

• Caring for Children in the Community, National Institutes of Health
• CADPRC In Developmental Epidemiology, National Institutes of Health

John A. Barefoot (Medical Psychology)

• Hostility Depression Social Environment and CHD Risk
• National Institutes of Health

Jean C. Beckham (Medical Psychology)

• Assessment Of Hostility And Health In Veterans With PTSD, National Institutes of Health
• Smoking & Anxiety In Posttraumatic Stress Disorder, National Institutes of Health

Lenor B. Behar (Medical Psychology)

• Effectiveness of Child and Family Services
• Child Traumatic Stress

Dan G. Blazer (Geriatric Psychiatry, Social Psychiatry)

• Epidemiology of psychiatric and physical disability in older adults

James Blumenthal (Behavioral Psychiatry)

• Stress & Myocardial Ischemia: Mechanisms & Treatment, National Institutes of Health
• Exercise Training And Depression In Older Adults, National Institutes of Health
• Behavioral Treatment Of Fibromyalgia, University of Ohio
• Behavioral Treatment of Hypertension, National Institutes of Health
• Enhancing Recovery in Coronary Heart Disease (ENRICHED), National Institutes of Health
• ENRICHED Ancillary Study: HRV and Low Social Support, Dana Foundation
• Depression and Mortality Following Myocardial Infarction, Washington University
• Telephone stress management in patients awaiting lung transplantation, National Institutes of Health

Hayden Bosworth (Medical Psychology)

• Health Service Research and Development Post-doctoral Fellowship Program, Veterans Affairs
• Health Service Research and Development Pre-doctoral Fellowship Program, Veterans Affairs
• Antecedents of Hypertension Control Among Veteran Patients: A Pilot Study, Veterans Affairs
• HIV Seroprevalence and risks in Veterans with severe mental illness, Veterans Affairs
• Measuring the Quality of Dying, Veterans Affairs
• Prospective comparison of colonic imaging tests, National Cancer Institute
• Promoting informed decision-making about estrogen replacement., National Cancer Institute

Barbara J. Burns (Social & Community Psych)

• Therapeutic Foster Care in a System Of Care, Case Western Reserve University
• Home and Community-Based Mental Health Services Research, Medical University of South Carolina
• Mental Health Service Across Child Welfare Agencies, Case Western

Marian I. Butterfield (Biological Psychiatry)

• Women's mental health across the reproductive life cycle, gender differences health risks (HIV, Hepatitis B/C) and behaviors, victimization PTSD and health, mental disorders in primary care
• HIV seroprevalence and risks Veterans With Severe Mental Illness - VA Epidemiologic Research and Information Center
• Mirtazapine in PTSD --VA site, Organon Inc.
• Formats for assessing HIV risks
• Women Veterans Comprehensive Health Center: VA Center of Excellence in Women's Health
• Women's Health Fellowship VA Office of Academic Affairs Post residency training in women's health and health services research

Frederick Cassidy (Biological Psychiatry)

• A Follow-up Study of Patients Completing Protocol #CNS-1879-001,
• A Placebo-Controlled Study in Depressed Inpatients Undergoing Electroconvulsive Therapy, CATO
• Noradrenergic Mechanism of ECT in the Treatment of Depression, DUMC Small Research Grant
• Subtypes of Manic States: External Validation with Adenylyl Cyclase, National Alliance for Research on Schizophrenia & Depression

Sheila Collins (Biological Psychiatry)

• Mechanisms Regulating Expression Of The Ucp2 Gene, National Institutes of Health
• Sequalae of Chronic B3-agonist Exposure in Dogs: BAT Up-regulation and Desensitization of Cardiovascular and Metabolic Responses, Merck Research Laboratories
• B3-Adrenergic Receptors and MAP Kinase Signaling, National Institutes of Health
• Transcription And Function Of Adipocyte B3AR In Obesity, National Institutes of Health

Kathryn M. Connor (Biological Psychiatry)

• A study of Kava vs Placebo in Generalized Anxiety Disorder; PureWorld Botanicals, Inc
• Changes in Heart Rate Variability in patients with depression treated with paroxetine vs. venlafaxine
• Study of St. Johns' wort in anxiety disorders
• Placebo controlled study of Kava vs. Venlafaxine in generalized anxiety disorder, NIMH
• Placebo-controlled study of gepirone in atypical depression, Organon, Inc.
• A double-blind, placebo-controlled study of pagaclone in generalized anxiety disorder, Pfizer Pharmaceuticals, Inc.
• Placebo controlled studies of botanical treatments in social anxiety, NCCAM
• A survey to assess health, hardiness, and spiritual beliefs in the community
• Placebo-controlled study of chromium piccolinate in atyipcal depression, Nutrition 21
• Development of a self rating scale for Generalized Anxiety Disorder, Wyeth Ayerst, Inc
• Assessment of the prevalence and health utilization of PTSD in primary care, Pfizer Pharmaceuticals

Elizabeth Costello (Child & Adolescent Psych)

• Vulnerability to Drug Abuse: A Test of Competing Models, National Institutes of Health
• The Translation and Adaptation into Spanish CAPA, Wt Grant Fund
• Applying Developmental Epidemiology to Youth Services, National Institutes of Health
• Minority Supplement to Vulnerability to Drug Abuse: A Test of Competing Models, National Institutes of Health
• Development of Reports for Training Purposes, State of North Carolina

Jonathan Davidson (Outpatient Psychiatry)

• Protocol 107 - A Multi-center, Randomized, Double-Blind, Parallel-Group, Placebo Controlled, Dose-Range Finding Trial with Social Phobia, Novartis Pharmaceuticals Corporation
• Treatment of Generalized Anxiety Disorder, Madis Botanicals Inc.
• Family Study of Chronic Post-Traumatic Stress Disorder, National Institutes of Health
• Maintenance in Posttraumatic Stress Disorder, National Institutes of Health
• Treatment of Obsessive Compulsive Disorder (OCD), Roche
• Prevalence and Health Utilization of PTSD in Primary Care, Pfizer Pharmaceuticals
• Discontinuation Study in Social Phobia, Hoffman-LaRoche
• Depressive Disorder, National Institutes of Health
• Study of Treatment in Major Depressive Disorders, Pharmacia & UpJohn Inc.
• A Placebo-Controlled Trial In Social Phobia, Parke-Davis Pharmaceutical Company
• Treatment of Post Traumatic Stress Disorder: Protocol F1D-MC-X055, Eli Lilly Corporation
• Social Phobia With Substance Abuse, SmithKline Beecham Pharmaceuticals
• In The Treatment Of Social Phobia, Bristol-Myers Squibb
• Treatment Of Post-Traumatic Stress Disorder, GlaxoWellcome
• Patches in the Treatment Of Anxious Outpatients, Bristol-Myers Squibb
• Behavior Therapy In Social Phobia, National Institutes of Health
• Treatment of Generalized Social Phobia, Smith Klein Beecham
• Graduate Medical Training Fellowship: Psychiatric Clinical Research and Drug Development, GlaxoWellcome
• PTSD Outpatients, Pfizer
• Social Phobia, Warner-Lambert Co
• Solvay, Consumer Contact with the ADAA
• Anxiety Disorder Treatment of Post-Traumatic Stress Disorder, Bristol Myers Squibb
• Social Phobia, Lilly
• Treatment of Outpatients with MDD, Merck & Co
• Patients with Moderate to Severe Major Depressive Disorder, Novartis Pharmaceuticals Corporation

Michael D De Bellis (Child & Adolescent Psych)

• Director, Healthy Childhood Brain Development and Developmental Traumatology Research Program
• PTSD & Childhood Sexual Abuse: Psychobiology , National Institutes of Health-NIMH
• Child Neglect: Psychobiological Consequences , National Institutes of Health-NIMH Adolescent Alcohol Abuse, PTSD & Hippocampal Development National Institute on Alcohol Abuse and Alcoholism
• Functional and Anatomical MRI in Maltreated Children with Posttraumatic Stress Disorder National Alliance for Research on Schizophrenia and Depression (NARSAD)

Murali Doraiswamy (Biological Psychiatry)

• Alzheimer's Disease In the Community Setting, Novartis Pharmaceuticals Corporation
• Alzheimer's Disease, Merck & Company Inc.
• Major Depressive Disorder, National Institutes of Health
• Major Depression, Eli Lilly Corporation
• Quality of Life In Elderly Medical Patients During Antidepressant Therapy, GlaxoWellcome
• Sandoz Educational Fund, Sandoz Pharmeuticals Corporation
• Cerebral Blood Flow Measurement In Late Life Depression Us, National Alliance For Research On Schizophrenia & Depression
• Apolipoprotein E Type 4 Allele And Cerebral Metabolism in Relatives at Risk for Alzheimer's Disease, American Federation for Aging Research
• Treatment of Major Depression, Eli Lilly & Co
• Major Depression, Eli Lilly & Co
• Magnetic Resonance Markers of Degeneration in Alzheimer's Disease, Bayer Corporation
• Cerebral Blood Flow Measurements in Late-Life Depression Using MRI, National Alliance for Research on Schizophrenia & Depression
• Neuroimaging In HIV Infection, University of North Carolina-Chapel Hill

Lawrence Dunn (Biological Psychiatry)

• On Health Outcomes with Schizophrenia and Schizoaffective Disorders, Zeneca Inc.

Jack D. Edinger (Medical Psychology)

• Dose Response Effects Of Behavioral Insomnia Therapies, National Institutes of Health
• Cognitive-Behavioral Therapy for Primary Insomnia, National Institutes of Health

Christopher Edwards (Medical Psychology)

• The Relationship Between Depression and Glycemic Control in Type I and Type II - Post-Doc Fellow, National Alliance for Research on Schizophrenia & Depression

Helen Link Egger (Child and Adolescent Psychiatry)

• Anxiety Disorders in Preschoolers
• The Genetic Developmental Epidemiology of High Reactivity - study of anxiety and biological reactivity in four year old twins

Everett H. Ellinwood (Biological Psychiatry)

• Presynaptic Dopamine Mechanisms After Chronic Cocaine, National Institutes of Health
• Parameters of Treatment Dosing, University of California - San Francisco
• Evaluation of Xeno-graft Transplantation Neurotrophic Therapy & Gene Therapy in Hydroxydopamine Model in Parkinson's Disease, Novartis Pharmaceuticals Corporation

Jeff Epstein (Medical Psychology)

• Neuropsychological Functioning in Adults with ADHD, DUMC Small Research Grant
• Neuropsychological Functioning in Adults with ADHD, National Institutes of Health
• Promoting Evidence-Based ADHD Treatment in the Community, NIMH
• Multimodal Treatment Study of Children with ADHD, NIMH
• Functional Neuroanatomical Deficits in ADHD Families, NIMH
• Examining Neuroanatomical Deficits in ADHD Patients, NIMH

John A. Fairbank (Medical Psychology)

• Relationships of Stress Exposures To Health In Gulf War Veterans Army Socioeconomic Consequences of Traumatic Stress, Research Triangle Institute

Elizabeth M.Z. Farmer (Medical Psychology)

• Effectiveness of mental health services for children and adolescents
• Patterns of care and outcomes for community-based care and systems of care
• Role of schools in children's mental health services
• Life course trajectories of youth with externalizing behavior disorders

Leslie M. Forman (Outpatient Psychiatry)

• Treatment of Elderly Subjects Residing in Nursing Homes or Assisted Care Facilities and Presenting with Alzheimer's Dementia and Psychoses or Other Selected Psychoses, Zeneca Inc.
• The Management Of Behavioral Disturbances and/or Psychosis in Demented Nursing Home Patients, Eli Lilly Corporation
• Management of Patients with Alzheimer's Disease in a Nursing Home Facility, Eisai America Inc.
• Major Depression After Myocardial Infarction (Sadhart), Pfizer

Kishore M. Gadde (General Psychiatry)

• Bupropion treatment of obesity and mild depressive symptoms Funding: GlaxoSmithKline
• Zonisamide in obesity Funding: Elan Pharma
• Hypocaloric diet and bupropion for obesity Funding: Obesity Research Network
• Interventions for olanzapine associated weight gain Funding: Eli Lilly
• Monoamine depletion in vascular depression Funding: NIH

Jeffrey Georgi (Biological Psychiatry)

• Family Care Program, Durham County Mental Health

Veeraindar Goli (Biological Psychiatry)

• Chronic Pain, Knoll Pharmaceutical
• Pain Associated with Diabetic Neuropathy, Wyeth-Ayerst

Lisa P. Gwyther (Aging Center)

• Alzheimer's Disease Research Center, Education Core Director, National Institute on Aging
• Home Care for Persons with Alzheimer's Disease and Other Dementias, AARP Andrus Foundation
• Stress, Serotonin Genes and Health Disparities, National Institute on Aging
• Ethical Decision Making in End-of-Life Care for Persons with Alzheimer's Disease, Greenwall Foundation
• U.S. Administration on Aging, Technical Assistant
• North Carolin Divison of Aging, Technical Assistant

Judith Hayes (Medical Psychology)

• Social Support, Functional Status and Depressive Disorders, NIMH
• Social Correlates of Depressive Symptoms in Late Life, National Institute on Aging
• Age of Onset of Unipolar and Bipolar Disorders, NIMH
• Bereavement in Late Life, National Institute on Aging

Diane Johnson (Medical Psychology)

• Treatment of Adults with ADHD and Varying Degrees of Anxiety and Depressive Symptoms, SmithKline Beecham
• A Study to Evaluate the Safety and Efficacy of Provigil (Modafinil) Administered to Adults with ADHD, Cephalon
• A Withdrawal Trial of d-threo-Methylphenidate Hydrochloride in Children with ADHD, Celgene
• A Study of Methylphenidate Transdermal System in Pediatric Patients with ADHD, Noven
• A Study of Guanfacine Hydrochloride Administered to Children with ADHD, Shire

Francis Keefe (Medical Psychology)

• Cognitive Behavioral Treatments for Arthritis Pain, NIAR
• Coping with Osteoarthritic Knee Pain, NIAR
• Behavioral Treatment of Fibromyalgia, National Institutes of Health
• Enhancing Recovery in Coronary Heart Disease (ENRICHED), University of North Carolina - Chapel Hill
• Gender, Coping, and the Arthritis Pain Experience, NIAMS
• Spouse-Guided Pain Management Training for Cancer Pain, NCI
• Clinician-Assisted Emotional Disclosure: Effects on Rheumatoid Arthritis, Arthritis Foundation
• Analysis of Clinician-Assisted Emotional Disclosure, Fetzer Institute
• Fluoxetine and Behavior Therapy in Social Phobia, NIMH

Richard Keefe (Medical Psychology)

• Working Memory Deficits and Prefrontal Dysfunction in Schizophrenia, National Alliance for Research on Schizophrenia & Depression
• Neural Circuitry And Cognitive Function In Schizophrenia, National Institutes of Health
• Psychotic Symptom Reduction, Janssen Pharmaceutical
• Development of the Brief Assessment of Cognition in Schizophrenia (Eli Lilly)
• Director, Neurocognitive Assessment Unit "Clinical Antipsychotic Trials of Intervention Effectivness" (NIMH)
• Motor Imagery and Brain Function (unfunded) Study of whether repeated visualization of motor movements increases brain activation in motor cortex
• Personality Factors in Rehabilitation Following ACL Surgery

Harold G. Koenig (Geriatric Psychiatry)

• Study the Effects of Religion/Spirituality on use of Health Services by a Group of High Utilizers, Mary Duke Biddle Foundation
• Impact Of Religion And Spirituality On Health Service Use, Arthur Vining Davis
• Impact Of Religion And Spirituality On Health Service Use, Fetzer Institute
• Impact Of Religion & Spirituality On Health Service Use, Sir John Templeton Foundation
• Depressive Disorder in Hospitalized Medically Ill Elders, National Institutes of Health
• Measuring Religious Coping: A Follow-up Study, Bowling Green State

Deborah Koltai (Medical Psychology)

• A Perspective Cohort Study Of Estuary-Associated Syndrome in Coastal North Carolina, University of North Carolina-Chapel Hill

Ranga R. Krishnan (Affective Disorders)

• Treatment of Elderly Outpatients With Major Depression, Pfizer Pharmaceuticals, Sandoz Pharmeuticals Corporation
• Brief Cognitive Screen - Caregiver Version, Pfizer Pharmaceuticals
• Alzheimer's Disease, International Clinical Research Corp
• Relationship of MRI Hyperintensities to Treatment Response in Geriatric Depression, Rhode Island Hospital
• Depressed Patient at Least 75 Years of Age, Forest Laboratories NY
• Bipolar Disorder in Late Life, National Institutes of Health
• Patients with Dementia Associated with Cerebrovascular Disease, Eisai America Inc.
• Genetic Imaging Study In Bipolar Disorder, National Alliance For Research On Schizophrenia & Depression
• Alzheimer's Disease -- Antemortem Markers, National Institutes of Health
• The Treatment Of Behavioral Manifestations of Alzheimer's Disease in Outpatients, Pfizer Pharmaceuticals
• Patients with Alzheimer's Disease, Eisai America Inc.
• Depression In Elderly Cardiac Patients, National Institutes of Health, Pfizer Pharmaceuticals
• Time to Diagnosis of Probable Alzheimer's Disease in At-Risk Subjects -- Data Management and Analysis Center, Novartis Pharmaceuticals Corporation
• CRC Study of Depression, National Institutes of Health
• Depression in Nursing Placement of Alzheimer's Disease (AD) Patients, Battelle Memorial Institute, Forest Laboratories, Inc
• Depression in Late Life, National Institutes of Health
• Cortisol Cognition Brain Atrophy and Depression, National Institutes of Health
• Depression in Elderly Cardiac Patients, National Institutes of Health
• Patients with Probable Mild to Moderate Alzheimer's Disease, Novartis
• Patients with Probable Mild to Moderate Alzheimer's Disease, Sandoz

Andrew D. Krystal (Outpatient Psychiatry)

• Improving ECT Effectiveness Through ICTAL EEG Analysis, National Institutes of Health
• Magnetic Resonance Spectroscopic and Electrophysiologic Correlates of Major Depression and its Response to Electroconvulsive Therapy, National Alliance For Research On Schizophrenia & Depression
• A Multicenter, Randomized, Double-Blind, Three-Period Crossover Study to Evaluate Residual Sedation after a Nocturnal Awakening in Patients with Sleep Maintenance Insomnia, Wyeth-Ayerst Research Inc.
• Optimizing ECT Stimulus Dosing Using the ICTAL EEG, National Institutes of Health

James Lane (Medical Psychology)

• Caffeine Effects on Stress Reactivity, National Institutes of Health
• Caffeine Effects on Stress Reactivity - Minority Supplement, National Institutes of Health

Tong H. Lee (Biological Psychiatry)

• Dopamine Presynaptic Inhibition and Cocaine Pretreatment, DUMC Small Research Grts
• Dopamine Presynaptic Inhibition and Cocaine Treatment, National Institutes of Health

Edward D. Levin (Biological Psychiatry)

• Proposal For Renewing Rjr-Leon Golberg Memorial Fellowship, R. J. Reynolds Industries
• Chronic Nicotine-Infusion Induced Memory Improvement, National Institutes of Health
• Integrated Toxicology Training Program, National Institutes of Health
• Cognitive Aspects Of Nicotinic Interactions With Atypical Antipsychotics, National Alliance for Research on Schizophrenia & Depression
• Neurotoxic Effects of Adult and Developmental Exposure to Pfiesteria Toxin, Environmental Protection Agency
• Collaborative Research Training in Environmental Toxicology, Environmental Protection Agency
• Symposium: Attention as a Target of Intoxication: Insights and Methods from Studies of Drug Abuse, National Institutes of Health

Isaac Lipkus (Medical Psychology)

• Using Tailored Messages to Improve Colroctal Screening, AMC Cancer Center
• Recruiting Teen Smokers Into A Self-Help Quit Smoking Program, National Institutes of Health
• Mammography Screening Among African-American Women with a Family History of Breast Cancer, Army

Thomas R. Lynch (Medical Psychology)

• Dialectical Behavior Therapy for Depressed Older Adults, National Institutes of Health
• A Comparison Between Dialectical Behavior Skills, Group Cognitive Therapy, and Pharmacotherapy in the Treatment of Depression Among Older Adults, Duke Small Research Grt.
• Using Magnetic Resonance Imaging to Examine Conditioning Salicncc and Habituation to Emotional Stimuli in Depression, National Alliance for Research on Schizophrenia & Depression
• Treatment of Elderly Depression with Axis II Comorbidity; NIMH
• Treatment of Old-Age Depression with Axis II Comorbidity; Hartford Foundation
• Dialectical Behavior Therapy for Depressed Older Adults, NIMH
• Comparison between cognitive and neurobiological models of suicidal behavior among depressed elderly
• Distraction versus Suppression of Suicidal Urges: Effects of Associational Learning, American Foundation for Suicide Prevention
• Conte Center for the Neuroscience of Depression-Proj 3, National Institutes of Health
• A Mindfulness Intervention for Treatment of Co-Morbid Depression in Lung Cancer Patients: A Pilot Study Duke Cancer Prevention, Detection and Control Research Program (PREP)
• Using Magnetic Resonance Imaging to examine Conditioning Salience and Habituation to Emotional Stimuli in Depression, National Alliance for Research on Schizophrenia and Depression, NARSAD
• Clinician-Assisted Emotional Disclosure: Effects on Rheumatoid Arthritis, Arthritis Foundation

David J. Madden (Medical Psychology)

• Age and Selective Attention in Visual Search, National Institutes of Health
• Neuroimaging of Age-Related Cognitive Changes, National Institutes of Health

John S. March (Child & Adolescent Psych)

• Research In Pediatric Anxiety Disorders, National Institutes of Health
• Treatment Of Pediatric Obsessive-Compulsive Disorder, National Institutes of Health
• Multi-modal Trauma Treatment In Hamlet, National Institutes of Health
• Effectiveness of Treatment for Adolescents with Major Depression, National Institutes of Health
• Study of Children and Adolescents with PTSD, Solvay Pharmaceutical
• Adolescent Social Phobia Research Fund, Pfizer
• Children and Adolescents (Aged 6 to 17) with GAD, Bristol-Myers Squibb

Prakash Masand (Biological Psychiatry)

• Irritable bowel syndrme and its relationship to psychiatric illness
• Randomized placebo control trial of paroxetine CR in irritable bowel syndrome
• Randomized placebo control trial of paroxetine CR in fibromyalgia
• Atypical antipsychotics and weight gain
• Atypical antipsychotics and diabetes mellitus
• Role of atypical antipsychotics and delirium

Joseph P. McEvoy (Biological Psychiatry)

• Antipsychotic Activity Hospitalized Schizophrenic Patients, Merck & Company Inc.
• Therapy to Mood Stabilizers in the Treatment of the Manic Phase of Bipolar Disorder, Janssen Pharmaceuticals
• Treatment of Schizophrenia, Pharmacia/Upjohn
• Schizophrenic Patients, Sanofi Winthrop Pharmaceuticals
• Cognition in Schizophrenia, Alza Corporation and Ppd Inc.
• Smoking and Bipolar I Disorder, National Alliance for Research on Schizophrenia & Depression
• Schizophrenic Patients, Sanofi Winthrop Pharmaceuticals
• Allelic Variation in Schizophrenia (FID-MC-HGGL(a)), Innovex
• An Open Extension Study Evaluating, Pfizer Pharmaceuticals

Hoechst Marion Roussel Inc.

• Schizophrenia and Schizoaffective Disorder Study #245-102-5009, Pfizer Pharmaceuticals
• Schizophrenic and Schizoaffective Patients, Hoechst Marion Roussel Inc.
• Schizophrenic and Schizoaffective Patients, Hoechst Marion Roussel Inc.
• The Treatment Of Bipolar Disorder, Manic or Mixed, Eli Lilly Corporation
• The Treatment Of Acutely Maniac Patients with Bipolar Disorder, Abbott Laboratories
• In First-Episode Psychotic Disorders, Eli Lilly Corporation
• Schizophrenia and Schizoaffective Disorder, Janssen Pharmaceuticals
• In Chronic Schizophrenia and the Companion Study: Open-Label Study of Olanzapine Treatment, Eli Lilly Corporation
• Treatment of an Acute Manic Episode in Patients with Bipolar Disorder, GlaxoWellcome
• Subjects with Mania, Pfizer Pharmaceuticals
• Smoking Schizophrenia and Atypical Anti-psychotics, Janssen Pharmaceuticals
• Treatment of Schizophrenia - RIS USA-113, Janssen Pharmaceuticals In Patients with Psychosis, Berger-Boyer & Associates Inc.
• Contract Agreement: Smoking, Schizophrenia and Atypical Antipsychotics, Janssen Research

Scott D. Moore (Biological Psychiatry)

• Ethanol Actions in the Amygdala in Vitro Preparation, National Institutes of Health

Paul Nagy (Child & Adolescent Psych)

• Goldstein Grant, National Institutes of Health
• Substance Abuse/Mental Health/HIV/AIDS Cost Study (SAMHHACS), National Institutes of Health

Jed E. Rose (Biological Psychiatry)

• Neuro-imaging Techniques For The Analysis Of Nicotine Addiction, Charles A. Dana Foundation
• Smoking Cessation, American Cancer Society
• Nicotine Tolerance and Blockade in Cigarette Smokers, National Institutes of Health
• Nicotinic Influences on Alcohol Use and Dependence, National Institutes of Health

Susan S. Schiffman (Medical Psychology)

• Gustatory and Olfactory changes with Age, National Institutes of Health
• A Taste Perception Evaluation in Adult Asthma Patients, Forest Laboratories NY
• Orange Sodas & Colas: Factors that Influence Volume Consumed Pepsi Medications Effect on Taste and Smell in HIV, National Institutes of Health
• Human Sensory Evaluations, Nutra Sweet Co
• Use of Electronic Nose to Characterize Microorganisms in Heating/Air Conditioning Systems, Center for Indoor Air
• Taste Perception of Antibiotic Formulations, TAP Holdings, Inc

Rochelle D. Schwartz-Bloom (Biological Psychiatry)

• Cerebral Ischemia and GABAergic Neurotransmission, National Institutes of Health
• Drugs: Integrating High School Biology & Chemistry, National Institutes of Health
• Recruiting Teen Smokers Into A Self-Help Quit Smoking Program, National Institutes of Health
• Nicotinic Receptor Regulation in Smokers in Smoking Cessation Trials, National Institutes of Health

Andrew Sherwood (Medical Psychology)

• Menopausal Effects In Cardiovascular Stress Responses, National Institutes of Health
• Biobehavioral Mechanisms of Blood Pressure Regulation, National Institutes of Health
• Stress & Heart Failure: Prognosis and Mechanisms, National Institutes of Health
• Heart Disease in Women: Estrogen Effects on Hemodynamics, National Institutes of Health

Ilene C. Siegler (Medical Psychology)

• Surveillance And Analysis Of The UNC Alumni Heart Study, National Institutes of Health
• Improving Cancer Risk Communication, National Institutes of Health
• Models of Personality, Health and Disease in Adulthood, National Institutes of Health
• Stress of caregiving, National Insititute on Aging
• Assessment of functional health in centenarians, University of Georgia, National Institute on Aging

Susan G. Silva (Medial Psychology)

• Treatment for Adolescents with Depression (TADS), National Institute of Mental Health
• Cooperative Multi-Center Reproductive Medicine Network, National Institute of Health
• HIV: Neuropsychiatric and Psychoimmune Relationships, National Institute of Mental Health

Anna Stout (Medical Psychology)

• Premenstrual Dysphoric Disorder, Pfizer

David C. Steffens (Geriatric Psychiatry)

• Geriatric Depression: Apoliporotein E And Dementia Risk, National Institutes of Health
• Geriatric Depression: Risk Factors for Adverse Outcome, National Institute of Health

Edward C. Suarez (Medical Psychology)

• Hostility & CHD:SNS Lipid & Cell Molecular Mechanisms, National Institutes of Health
• Depression & CHD: Cellular-Molecular Mechanisms National Heart, Lung and Blood
• Socioeconomic Status, Psychosocial Factors and Biological Mechanisms of CHD National Heart, Lung and Blood

Richard S. Surwit (Behavioral Psychiatry)

• Effects of PPAR Ligands on Obesity & Insulin Sensitivity in Fat-fed B6 Mice, Merck & Company Inc.
• Medical Center Community Partnership For Clinical Trials in Obesity, Robert Wood Johnson Foundation
• Relationship of Depression to Glycemic Control in the Kaiser NC Patient Population, Pfizer Pharmaceuticals
• Investigation of SUR1 Agonists in Treatment of Diabetes and Obesity, GlaxoWellcome
• Differential Response to CBT in Type 1 and Type 2 Diabetes. National Institutes of Health

Jeffrey W. Swanson (Social & Community Psychiatry)

• Schizophrenia Care and Assessment Programî Ü Assessing the cost effectiveness of new treatments for schizophrenia in six systems of care and implementing a standardized instrument for monitoring outcomes in schizophrenia care., Eli Lilly and Company / The MEDSTAT Group
• The Effectiveness of Outpatient CommitmentîÜ Bridging science and service. Continuation of a six year study on involuntary mental health treatment of seriously mentally ill subjects in North Carolina., National Institute of Mental Health
• Epidemiologic consultant and Research Health Scientist with ñThe Epidemiologic Research and Information Centerî. (ERIC) Durham Veterans Affairs Medical Center
• HIV Seroprevalence and Risks in Veterans with Severe Mental Illnessî Ü Prevalence of HIV risk behaviors and HIV infection; utilization of health services over time., Department of Veterans Affairs
• Postdoctoral Training Program in Mental Health Services, University of North Carolina Ü Chapel Hill
• Relationship between Clinical Characteristics, Illicit Drug Use and Treatment Outcomes in Schizophreniaî, The Theodore & Vada Stanley Foundation
• Formats for Assessing HIV Risk in Severely Mentally Ill Peopleî Ü Compares trained interviewers and computer assisted interviews (CAI) as techniques for obtaining self-report on HIV risk from subjects with serious mental illness., Duke Subcontract Ü National Institute of Mental Health

Marvin S. Swartz (Social & Community Psych)

• Program On Services Research For People With SMD, University of North Carolina-Chapel Hill
• Postdoctoral Training program in Mental Health Services, University of North Carolina-Chapel Hill
• Research Study of Involuntary Mental Health Treatment, Policy Research Associates
• How Does Illicit Drug Use Lead To Poor Treatment Outcomes in Schizophrenia, Stanley Foundation
• Effectiveness Of Involuntary Outpatient Commitment, National Institutes of Health
• NIMH Postdoctoral Training Program in Mental Health Services, University of North Carolina
• Mental Health Services Research
• Violence and Mental Illness
• Mandated Community Treatement, MacArthur Foundation

H. Scott Swartzwelder (Medical Psychology)

• Developmental CNS Sensitivity To Ethanol, National Institutes of Health
• Perinatal Choline Exposure and Hippocampal Function, Boston University

Larry A. Tupler (Medical Psychology)

• Brain Structure and Cognition in Elderly with APOE E4, National Institutes of Health

Indu Varia (Biological Psychiatry)

• Non-cardiac chest pain, Pfizer Pharmaceuticals, Inc.
• Treatment of Social Anxiety Disorder, Forest Lab. Inc.
• Treatment of Generalized Anxiety Disorder, Forest Lab. Inc.
• Coping skills training and Sertraline in the Management of Non-Cardiac Chest Pain
• Treatment of Adults with ADD and Co-Morbid Anxiety and Depressive symptoms

Barbara K. Walter (Medical Psychology)

• Traumatic Brain Injury: Surveillance of Secondary Conditions and Quality of Life, University of North Carolina-Chapel Hill

Lana Watkins (Medical Psychology)

• Anxiety & Autonomic Nervous System Cardiac Control in Coronary Heart Disease, National Institutes of Health
• Antidepressants & Heart Rate Variability: Effects of Selective Serotonin Reuptake Inhibition, Smith-Kline-Beechum
• Depression & Heart Rate Variability Following Myocardial Infarction, National Institutes of Health

Richard Weiner (Biological Psychiatry)

• Safety and efficacy of electroconvulsive therapy
• EEG correlates of ECT

Richard H. Weisler (Biological Psychiatry)

• Generalized Anxiety Disorder, Parke-Davis Pharmaceutical Company

William C. Wetsel (Medical Psychology)

• Genetic Rescue Of Pro-LHRH Processing In Cpefat Mice, National Institutes of Health
• Neurochemical, Neuroendocrine and Behavioral Analysis Of Dopamine Transporter Knockout Mice Treated with Neuroleptic Compounds, National Alliance For Research On Schizophrenia & Depression
• Cognitive Deficits in Dopamine Transporter Knockout Mice: An Animal Model of Human ADHD, March of Dimes

Redford B. Williams (Behavioral Psychiatry)

• Biobehavioral Factors in Coronary Heart Disease, National Institutes of Health
• Behavioral Mechanisms In Cardiovascular Diseases, National Institutes of Health
• Hostile Personality, Eli Lilly
• Stress and Behavior in Health and Disease, National Institutes of Health
• Psychosocial risk factors for cardiovascular and other major illnesses
• Biobehavioral mechanisms whereby psychosocial factors affect health and disease
• The roles of the brain serotonin system and genes that affect sertonin functions in mediating psychosocial risk factors and biobehavioral mechanisms
• Mechanisms responsible for the "socioeconomic gradient" of health and disease
• Serotonergic genes as moderators of the effects of caring for an Alzheimers' Disease patient on psychosocial and biobehavioral characteristics
• Behavioral treatments to ameliorate the health damaging effects of psychosocial risk factors

William H. Wilson (Medical Psychology)

• Early Use of Marijuana and Brain Morphology and Function, National Institutes of Health

William Wohlgemuth (Medical Psychology)

• Combined Cognitive-Behavioral/Hypnotic Treatment for Primary Insomnia, Duke Small Research Grant

Psychotherapy Supervisors

James H. Carter, M.D.

Dr. Carter completed a combined psychiatric residency at Duke and Dorothea Dix Hospital. He subsequently performed a fellowship in Community Psychiatry at Duke before joining the faculty. Dr. Carter's career has mainly focused on minority mental health services and treatment and he has become a pioneer in the field of Cultural Psychiatry. He is extensively published in scientific journals and textbooks in the areas of Correctional Psychiatry, Geropsychiatry, and the psychotherapeutic treatment of African Americans.

Allan Chrisman, M.D.

Dr. Chrisman had his psychiatry training at Harvard Medical School . He did an adult psychiatry residency at McLean Hospital and a Child and Adolescent Fellowship at Beth Israel Hospital. During the adult residency, he entered psychoanalysis as part of the psychotherapy training experience. Throughout the adult and child/adolescent programs he received psychoanalytically oriented psychotherapy training. Additionally he also received training in hypnosis, and short-term psychotherapy. His psychotherapy experiences are in both in-patient and outpatient settings. He continued his post residency psychotherapy training in short-term group and individual treatment while working at the Harvard Community Health Plan. Dr. Chrisman's psychotherapeutic approach utilizes his understanding of developmental issues gained from the child and adolescent training along with a biopsychosocial model of care.

Leonard Handelsman, M.D.

Dr. Handelsman performed his psychiatric residency at the Albert Einstein College of Medicine and subsequently underwent a Fellowship in Substance Abuse at the Mt. Sinai School of Medicine. Prior to his psychiatric career, he was a Fulbright Scholar and a Woodrow Wilson Fellow in Sociology at the University of Chicago. Dr. Handelsman has become an expert in Addition Psychiatry and is Head of the Psychiatry Research Program in HIV Neuropsychiatric Disorders at Duke. He is also Director of Duke's Psychiatry Outpatient Clinic and co-facilitates the clinic's resident process group. Dr. Handelsman has a neurobiological and phenomenological orientation to treatment in general and uses an eclectic mixture of perspectives and techniques.

David M. Hawkins, M.D., CGP

Dr. Hawkins received his psychiatric training at Duke and was on the faculty until 1990, when I went into private practice. He specializes in psychodynamic psychotherapy, both individual and group, and offers post-graduate training in psychodynamic group psychotherapy in Chapel Hill and Atlanta. Dr. Hawkins is a past president of the American Academy of Psychotherapists as well as the American Group Psychotherapy Association.

He also heads the Group Psychotherapy elective for Duke and UNC Psychiatry residents, who after completing 2 years can become members of the American Group Psychotherapy Association.

Harold Kudler, M.D.

Dr. Kudler trained in psychiatry at Yale University School of Medicine during which time he served as Chief Resident at Yale New Haven Hospital and at the Yale Psychiatric Institute. He also performed two years of elective work as a clinician at the Yale Child Study Center. Dr. Kudler began psychoanalytic training through the UNC-Duke Psychoanalytic Training Program while on faculty at Duke and is now an advanced candidate in both Adult and Child psychoanalysis. He currently teaches seminars on psychological trauma for candidates through the training program and coordinates psychotherapy seminars for PGY 2 and 3 residents at Duke. Additionally, he is a founding Steering Committee member of the Psychoanalytic Psychotherapy Study Center of North Carolina as well as teacher and clinical supervisor. He has also served as a mentor for the American Psychoanalytic Association Fellowship Program for psychiatric residents. Dr. Kudler's focus is primarily psychodynamic with an aim of helping the residents apply psychoanalytic principles in work with a broad range of patients and situations. His hope is that residents develop an informed sense about their patients as well as themselves that may serve as the basis for decisions about the technical approach to be most helpful for a given patient at a particular time.

Thomas R. Lynch, Ph.D.

Dr. Lynch received his Ph.D. from Kent State University and postdoctoral training in Cognitive-Behavioral Therapy at Duke University. He is a national trainer of therapists in Dialectical Behavior Therapy and has been rated to adherence in DBT. Dr. Lynch's psychotherapy orientation consists of cognitive, behavioral, and dialectical behavioral approaches. He has expertise in cognitive-behavioral treatments of affective and personality disorders. His research focuses on examining the efficacy of Dialectical Behavior Therapy for treatment resistant elderly patients, and factors associated with affective disorders, personality disorders, and problems in emotion regulation.

William S. Meyer, MSW, BCD

Bill Meyer is a clinical social worker who has faculty appointments at Duke in both Psychiatry and Ob/Gyn. He has been a facilitator of residency process group and supervisor at the Psychiatric Outpatient Clinic for over 15 years. Bill has maintained an adult psychotherapy practice and continues to teach the course on technique at the Psychoanalytic Psychotherapy Study Center of North Carolina. He is the current president of the National Membership Committee On Psychoanalysis in Clinical Social Work. His major influences come from a range of primarily psychoanalytic authors. Bill believes that a psychoanalytic perspective is indispensable, whether one is doing an assessment, brief, supportive, or insight-oriented psychotherapy and that the relationship is central to all psychotherapeutic work.

Peter Z. Perault, M.D.

Dr. Perault performed his adult psychiatry residency and Child and Adolescent Fellowship at Duke. He subsequently received further psychiatric training as a Fellow in Psychiatry at the University of Connecticut Health Center before undergoing psychoanalytic training at the UNC-Duke Psychoanalytic Education Program. He is currently in private practice, but has academic appointments at both Duke and UNC Departments of Psychiatry where he gives seminars and supervises residents. Dr. Perault is also very active in the UNC-Duke Psychoanalytic Education Program and the Psychoanalytic Psychotherapy Study Center of North Carolina as both teaching analyst and instructor. Dr. Perault approaches psychoanalysis and psychotherapy from the perspective of self psychology, emphasizing an understanding of empathic attunement and self-objcet transference in healing the self esteem vulnerabilities that often underlies anxiety, depression, as well as obsessional and narcissistic difficulties.

Ingrid B. Pisetsky, M.D.

Dr. Pisetsky received her psychiatric training at Yale University and psychoanalytic training at the UNC-Duke Psychoanalytic Education Program. She has practiced psychiatry, psychotherapy, and psychoanalysis for over twenty years and has taught at Georgetown University, Duke, UNC, the Psychoanalytic Psychotherapy Study Center of North Carolina, and the UNC-Duke Psychoanalytic Education Program. Dr. Pisetsky's focus both in her own practice and in teaching is directed toward psychoanalysis, intensive psychodynamically oriented psychotherapy, and psychodynamically informed supportive psychotherapy.

Clive J. Robins, Ph.D., ABPP

Dr. Robins received his Ph.D. in clinical psychology from the State University of New York at Stony Brook. Dr. Robins trained in cognitive therapy at the Beck Institute for Cognitive Therapy and Research, and in Dialectical Behavior Therapy by Dr. Marsha Linehan. He has become a diplomate of the American Board of Professional Psychology in behavioral psychology, and a certified cognitive therapist. Dr. Robins has provided numerous training workshops on those treatments internationally and has published more than 50 articles and books chapters on depression, borderline personality disorder, and cognitive-behavioral therapy. Additionally, he has been training psychology graduate students, interns, and postdoctoral fellows, psychiatry residents, and mental health clinicians of all disciplines in cognitive and behavioral therapies since 1982.

Philip M. Spiro, M.D.

Dr. Spiro performed his psychiatric residency at Duke and subsequently underwent further psychodynamic psychotherapy training at The Masterson Institute in New York. His approach to patients follows the psychotherapeutic model outlined by Dr. James Masterson which is specifically tailored to the treatment of personality disorders. This model is currently the only one which utilizes differential intervention based on the patient's specific intrapsychic structure. Though his approach and training are primarily psychodynamic, Dr. Spiro finds it frequently useful to integrate approaches from other disciplines (CBT, behavioral therapy, interpersonal therapy, and EMDR) while maintaining an essentially neutral psychodynamic orientation and frame. Dr. Spiro also offers a popular elective course titled, "Psychodynamic Models: Theory and Practice" which explores the main variants of psychoanalytic theory.

Marvin S. Swartz, M.D.

Dr. Swartz performed his psychiatric residency at Duke and has subsequently held numerous clinical positions within the Department of Psychiatry. Currently, he is Head of the Division of Social and Community Psychiatry and faculty coordinator for the rotation, which has both a placement and seminar component. Dr. Swartz has training and experience with individual and group psychodynamically oriented psychotherapy. However, his current practice is mainly supportive psychotherapy combined with medication management.

Nerine E. Tatham, M.D.

Dr. Tatham trained in psychiatry at the Albert Einstein College of Medicine/Montefiore Medical Center. She is currently one of the Psychiatry Attendings on the Williams inpatient unit at Duke. Dr. Tatham's psychotherapeutic approach is eclectic, but predominately focuses on a psychodynamic orientation. More recently, she has developed a growing interest in Dialectical Behavior Therapy.

Grace C. Thrall, M.D.

Dr. Thrall trained at the combined residency programs of the University of Connecticut and the Institute of Living, a private psychoanalytically-oriented treatment facility. She is currently the Director of Residency Education at Duke and is active in psychotherapy education. Dr. Thrall co-leads the Learning Psychotherapy course for PGY-1 residents and provides psychotherapy supervision for senior residents. Her favored tools are psychodynamic psychotherapy, time-limited dynamic psychotherapy, and cognitive-behavioral therapy for anxiety disorders. Discovering the dynamic aspects of any physician-patient encounter and using this understanding to therapeutic advantage is a particular interest of hers which makes her Friday supervision of residents in the outpatient clinic especially enjoyable. She has specific interests in the nature of the therapeutic alliance, mechanisms of change and the management of countertransference. Issues at the interface of psychiatry and spirituality are another specific interest, where she has explored possible psychological phenomena involved in forgiveness. Educationally, Dr. Thrall is working to develop measures of psychotherapy competency in psychiatric education that can be used in residency programs nationally.